Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

Authors:

Top Cited Papers
Open Access
Abstract
The optimal clinical management of women with BRCA1 and BRCA2 mutations depends on accurate age-specific cancer risk estimates. These can be used to estimate the absolute risk reduction from preventive strategies and to inform decisions about the age at which to commence cancer screening.1

This publication has 24 references indexed in Scilit: